首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Development of organometallic (organo‐transition metal) pharmaceuticals
Authors:Claire S Allardyce  Antoine Dorcier  Claudine Scolaro  Paul J Dyson
Institution:Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, EPFL-BCH, CH-1015 Lausanne, Switzerland
Abstract:This paper is aimed at introducing the organometallic chemist to the fascinating area of organometallic pharmaceuticals. It commences by identifying the properties of organometallic (transition metal) compounds that lend themselves to medical applications. Next, the specialized techniques and methods that are used to assess the medicinal properties of compounds are summarized, and although these techniques are not restricted to organometallic compounds, all examples are concerned with organometallic compounds. The design and evaluation of organometallic compounds for medicinal applications are described in context with the diseases they have been evaluated against, and areas are identified that may have most potential for organometallic pharmaceuticals. Some new results, including the first example of an organo‐osmium compound that might exhibit effective anticancer properties, are also described. Copyright © 2005 John Wiley & Sons, Ltd.
Keywords:bioorganometallic  transition‐metal‐based drugs  anticancer  antiviral  antimicrobial
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号